866-997-4948(US-Canada Toll Free)

Published on : Apr 27, 2016

The coronary stents market has been witnessing rapid growth in the U.S. due to growing number of patients affected with various heart-related ailments. Lifestyle and food habits are largely to be blamed for the large number of patients affected with coronary diseases across the U.S. According to the Centers for Disease Control and Prevention (CDC), around 610,000 people die of heart diseases in the United States. Heart disease has emerged as the leading cause of death among both men and women. Coronary Heart Disease or CHD is the most commonly occurring heart disease. In CHD, plaque starts building up inside the arteries leading to lessening or blockage of blood flow. Chest pain is the major symptom of coronary heart disease. It is estimated that about 47% of sudden cardiac deaths occur outside hospitals. 

DAPT Score to Evaluate Risks in Patients Receiving Coronary Stents

Around 1 million patients across the U.S. receive coronary stents every year. They are expected to undergo dual antiplatelet therapy, better known as DAPT, and use the combination of aspirin and another antiplatelet medication to prevent blood clot formation. According to a recent study published in the Journal of American Medical Association, a new tool might be helpful in letting physicians offer a more personalized treatment strategy to patients. The tool, known as DAPT score, lets individual assessment of risks and benefits of DAPT over one year in patients who have received coronary stents. This allows physicians determine that how long they need to treat patients with DAPT therapy.